Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice
Experimental Biology and Medicine · 2025
DOI: 10.3389/ebm.2025.10356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Biology and Medicine, 2025. Verfasst von Kim B Pedersen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, United States. Hauptthemen laut MEDLINE: Fatty Liver, Liver, Cannabinoids, Cannabis. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cannabis and cannabinoid mixtures have been linked to a variety of health benefits including pain mitigation, suppression of nausea produced by chemotherapeutic agents, anti-inflammatory effects, and effects on energy homeostasis, glucose, and lipid metabolism. The latter properties have led to the suggestion that these products could have therapeutic effects on the development of metabolic dysfunction-associated steatohepatitis (MASH) - a severe type of liver pathology in obese and diabetic patients. However, varying agonist and antagonistic properties of different cannabinoids on the endogenous cannabinoid system make prediction regarding hepatic effects and diet interactions difficult. The current study was designed to examine hepatic pathology following chronic administration of a cannabinoid mixture (NEPE14) at a dose equivalent to one previously demonstrating antihyperalgesic effects in rats. The effects of NEPE14 were investigated in a mouse model of MASH produced by feeding a Western diet rich in fat and simple sugars. After 24 weeks of NEPE14 administration, there was no hepatotoxicity in mice receiving the control diet and no significant exacerbation of MASH in mice receiving the Western diet. In conclusion, no chronic liver toxicity was observed, but there was also no evidence for protection against MASH by this product.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, United States.
- Department of Comparative Biomedical Sciences, Louisiana State University School of Veterinary Medicine, Baton Rouge, LA, United States.
- MilMed R&D Consulting LLC, Brunswick, MD, United States.
- Full Spectrum Omega Inc., Los Angeles, CA, United States.
Zitieren
APA
Pedersen, K. B., Jelesijevic, T., Morris, T. M., Melton, S. M., Henderson, A. S., Glenn, J. F., Davenport, G. J., Ronis, M. J. J., & Winsauer, P. J. (2025). Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice. Experimental Biology and Medicine. https://doi.org/10.3389/ebm.2025.10356
Vancouver
Pedersen KB, Jelesijevic T, Morris TM, Melton SM, Henderson AS, Glenn JF, et al. Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice. Experimental Biology and Medicine. 2025. doi:10.3389/ebm.2025.10356
BibTeX
@article{Pedersen2025,
author = {Pedersen, Kim B and Jelesijevic, Tomislav and Morris, Tamara M and Melton, Sarah M and Henderson, Ashley S and Glenn, John F and Davenport, Gregory J and Ronis, Martin J J and Winsauer, Peter J},
title = {Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice},
journal = {Experimental Biology and Medicine},
year = {2025},
doi = {10.3389/ebm.2025.10356}
}
EUVIMED